Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL993397 | 0.87 | CES1 (0.46) | SMN1; SMN2MAPTERCC5FEN1L3MBTL1 | |
| SCHEMBL13735831 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2MAPTERCC5FEN1HAO1 | |
| SCHEMBL3140047 | 0.78 | CES2 (0.48) | MAPTHAO1RAB9AGSK3BLMNA | |
| SCHEMBL28252458 | 0.78 | CES2 (0.48) | RAB9ANPC1PTPN1MEN1KMT2A | |
| SCHEMBL5046739 | 0.76 | CES2 (0.55) | SMN1; SMN2MAPTRAB9ANPC1PTPN1 | |
| SCHEMBL2162369 | 0.73 | CES2 (0.53) | RAB9ANPC1PTPN1GSK3BHPGD | |
| SCHEMBL7789534 | 0.72 | CES2 (0.56) | SMN1; SMN2MAPTRAB9AL3MBTL1LMNA | |
| SCHEMBL8746802 | 0.72 | TDP1 (0.58) | MAPTL3MBTL1GSK3BLMNAMEN1 | |
| SCHEMBL6512827 | 0.72 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPTERCC5FEN1HAO1 | |
| SCHEMBL7746452 | 0.72 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPTERCC5FEN1HAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414728-B2 | Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders | CENNERV PHARMA (S) PTE LTD (SG) | 2019-09-17 | — | — | US | disclosed |
| US-20180141907-A1 | USE OF TETRAHYDROPYRIDINES IN THE TREATMENT OF SODIUM CHANNEL RELATED DISEASE AND DISORDERS | CHAKRA BIOTECH PTE LTD (SG) | 2018-05-24 | — | — | US | disclosed |
| US-20170355676-A1 | USE OF TETRAHYDROPYRIDINES IN THE TREATMENT OF SODIUM CHANNEL RELATED DISEASE AND DISORDERS | CHAKRA BIOTECH PTE LTD (SG) | 2017-12-14 | — | — | US | disclosed |
| EP-3226865-A1 | USE OF TETRAHYDROPYRIDINES IN THE TREATMENT OF SODIUM CHANNEL RELATED DISEASE AND DISORDERS | Cennerv Pharma (S) Pte. Ltd. (SG) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016089304-A1 | USE OF TETRAHYDROPYRIDINES IN THE TREATMENT OF SODIUM CHANNEL RELATED DISEASE AND DISORDERS | CENNERV PHARMA (S) PTE. LTD. (SG) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414728-B2 | Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders | KCND2, KCNJ2, KCNH3 | SMN1; SMN2 605/4885MAPT 1688/4885ERCC5 4827/4885 |
| US-20170355676-A1 | USE OF TETRAHYDROPYRIDINES IN THE TREATMENT OF SODIUM CHANNEL RELATED DISEASE AND DISORDERS | KCND2, KCNJ2, KCNH3 | SMN1; SMN2 612/4885MAPT 1631/4885ERCC5 4823/4885 |
| US-20180141907-A1 | USE OF TETRAHYDROPYRIDINES IN THE TREATMENT OF SODIUM CHANNEL RELATED DISEASE AND DISORDERS | KCND2, KCNJ2, KCNH3 | SMN1; SMN2 612/4885MAPT 1631/4885ERCC5 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.